N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=11 Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms
Myopathic Symptoms
Primary: Number of Participants With Reduction in Myopathic Pain — 4; 4 Participants
Phase 3 N=39 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Pain · Weakness · Cramps
Primary: Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use — 53; 65 % of participants with pain reduction
Phase 4 N=52 Impact of Statin Therapy on Adaptations to Aerobic Exercise
Cardiovascular Diseases
Primary: Difference in Mitochondrial Respiratory Function — 2.29; -11.24; 44.88 pmols/s/mg — p=0.9530
Phase 4 N=68 Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
Mitochondrial Diseases
Primary: Difference in Mitochondrial Respiratory Function — 36; 32; -3 pmols/s/mg — p=0.6051
Phase 2 N=43 Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance
Hypercholesterolemia · Statin-Associated Myopathy
Primary: Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) >500 — 2; 1 Participants
N/A N=70 Effect of Succinylcholine on Patients Using Statins
Pain
Primary: Plasma Myoglobin Concentration — 46; 39; 71; 49 ug/l — p=0.018
Phase 3 N=33 Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy
Dyslipidemias
Primary: Peak Oxygen Consumption — 43.8; 51.6; 53.5 percentage of predicted value
N/A N=50 Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
Obesity · Fatty Liver, Nonalcoholic
Primary: Insulin-stimulated Glucose Uptake — 5.9; 5.9 mg/kg/minute
Phase 4 N=60 Self-Assessment Method for Statin Side-effects Or Nocebo
Adverse Effects · Cardiovascular Diseases · Hyperlipidemias
Primary: Mean Symptom Scores Across Statin, Placebo and no Treatment Periods — 16.3; 15.4; 8.0 units on a scale
Phase 4 N=27 Statin Therapy in Heart Failure: Potential Mechanisms of Benefit
Heart Failure, Congestive
Primary: LVEF (Left Ventricular Ejection Fraction) — 24; 28; 25; 24 percent ejection fraction — p=0.025
Phase 2 N=24 Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Sickle Cell Disease
Primary: Change in Frequency of Vaso-occlusive Pain Events, Before and After Treatment With Simvastatin — 0.2365; 0.1311 proportion of pain days — p=0.005
N/A N=42 Statin Therapy Versus Placebo Prior to Prostatectomy
Cancer · Prostate Cancer
Primary: Measure the Effect of Pre-operative Simvastatin Versus Placebo on the Mevalonate Pathway Synthesis and Target Activation in Benign and Malignant Prostate Tissue…
N/A N=50 Exercise, Statins, and the Metabolic Syndrome
Metabolic Syndrome · Obese · Sedentary
Primary: % Change in VO2max (Fitness) — 0; 10; 1.5 percentage change of VO2max — p=<0.05
N/A N=381 Statin Discontinuation in Advanced Illness
Palliative Medicine · Cardiovascular Disease
Primary: Proportion of Deaths Within 60 Days of Enrollment. — 0.203; 0.238 proportion of deaths
N/A N=80 Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
Parkinson Disease · Dyskinesia, Drug-Induced
Primary: Peak Unified Dyskinesia Rating Score (UDysRS) — 10.9; 10.8; 13.2 score on a scale — p=0.63
Phase 4 N=108 Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
Inflammation
Primary: Mean Change in Level: Week 16-baseline in Ena-78 — -111.2 pg/ml — p=0.15
Phase 2 N=116 Statin Therapy in Acute Influenza
Influenza
Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611
Phase 4 N=60 The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin
Dyslipidemias
Primary: Comparison Between XueZhiKang and Simvastatin on Fatigue Scores — 19.58; 21.58; 19.26; 19.33 units on a scale
Phase 4 N=9 Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
Cardiovascular Disease · Cardiomyopathy · Heart Disease
Primary: Change in Endothelial Progenitor Cells — -10.01; 5.19 Percentage of EPCs
Phase 4 N=75 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Hyperlipidemia · Insulin Resistance · Type 2 Diabetes
Primary: Steady-state Plasma Glucose (SSPG) — 130; 139 mg/dL — p=0.01
Phase 2 N=57 Statin/Vitamin D & Migraine Study
Migraine
Primary: Migraine Frequency: Change From Baseline 12-week Period to Weeks 1 to 12 — -8.0; 1.0 days
Phase 3 N=218 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Hyperlipidemia
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24 — -16.70; -54.50 percent change — p=<0.0001
Phase 3 N=602 PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
HIV-1 Infection
Primary: Physical Function: Rate of Change in Chair Rise Rate — -0.035; 0.07 rises/minute per year — p=0.31
Phase 4 N=134 A Study Comparing CoQ10 Levels While Taking 3 Different Statins
Hypercholesterolemia
Primary: Changes in Plasma CoQ10 Levels — -96.70; -110.42; -103.91; -721.09 μg/g
Phase 2 N=162 Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
Stroke · Rhabdomyolysis · Jaundice
Primary: Total Number of Participants With an Increase in Liver Function Tests (LFTs) — 1; 2 Participants
Phase 2 N=36 Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Diabetes Mellitus · Metabolic Syndrome X · Hypercholesterolemia
Primary: Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels — 2.1; 2.5 nmol/mL
N/A N=159 Genetically Guided Statin Therapy
Hypercholesterolemia · Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Primary: Morisky Medication Adherence Scale (MMAS) Score — 6.8; 6.9; 6.8; 7.1 units on a scale — p=0.96
N/A N=31,602 Cardiovascular Events Based On Statin Initiation In The Elderly
Cardiovascular · Dyslipidemia
Primary: Number of Participants With Post-index Cardiovascular (CV) Events — 700; 1012 Participants — p=<0.001
N/A N=78 Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe
Stable Angina
Primary: C-reactive Protein — -16; -11 Percentage — p=0.3